TX000045
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for TX000045, covering 2026-03-16 to 2026-03-27. Get the full timeline:
Most recent: Clinical Trial Update: A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study) [Phase 2]